| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | myriocin | CTRPv2 | pan-cancer | AAC | -0.0062 | 0.9 |
| mRNA | BRD-A02303741:carboplatin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.003 | 0.9 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.0037 | 0.9 |
| mRNA | BRD-K20514654 | CTRPv2 | pan-cancer | AAC | 0.0042 | 0.9 |
| mRNA | BMS-195614 | CTRPv2 | pan-cancer | AAC | -0.0029 | 0.9 |
| mRNA | PIK-93 | CTRPv2 | pan-cancer | AAC | 0.0024 | 0.9 |
| mRNA | paclitaxel | CCLE | pan-cancer | AAC | 0.0029 | 0.9 |
| mRNA | dacarbazine | CTRPv2 | pan-cancer | AAC | 0.002 | 0.9 |
| mRNA | ML334 diastereomer | CTRPv2 | pan-cancer | AAC | 0.0028 | 0.9 |
| mRNA | dexamethasone | CTRPv2 | pan-cancer | AAC | 0.0021 | 0.9 |